Presentation is loading. Please wait.

Presentation is loading. Please wait.

HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International.

Similar presentations


Presentation on theme: "HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International."— Presentation transcript:

1 HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International AIDS & Economics Network Pre-conference, Melbourne, July 2014 Emily Donaldson, AVAC Presenting on behalf of the HIV Vaccines & Microbicides Resource Tracking Working Group

2 Methodology Comprehensive and consistent investment data collection and disaggregation methodology since 2004 Data collection January – June 2014 HIV Vaccines & Microbicides Resource Tracking Working Group Data Sources: Public funders (447 grants) Philanthropic (141 grants) Industry (7 grants) R&D Categories: Preventive HIV vaccines (307 grants) Microbicides (84 grants) Pre-exposure prophylaxis (54 grants) Treatment as prevention (80 grants) Male circumcision (20 grants) Female condom (4 grants) Prevention of vertical transmission (24 grants) HSV-2 vaccines (22 grants) HIV cure (150 grants) Therapeutic HIV vaccines (45 grants)

3 Global HIV Prevention R&D Investment, 2009 – 2013 (US$ millions) US$1.26B US$1.31B US$1.28B US$1.27B US$1.22B HIV Vaccines & Microbicides Resource Tracking Working Group

4 Global HIV Prevention R&D Investment 2013 by Funder Type (US$ millions) HIV Vaccines & Microbicides Resource Tracking Working Group

5 Global HIV Prevention R&D Investment 2012 & 2013 (US$ millions) Funding SourceAmount 2013Amount 2012% Change from 2012 US Public-Sector % European Public- Sector % Other Governments % Philanthropic % Industry3734+9% All HIV Prevention R&D % HIV Vaccines & Microbicides Resource Tracking Working Group

6 2013 Investment and Year-Over-Year Change HIV Vaccines & Microbicides Resource Tracking Working Group

7 $154M 2013 International Development Funding HIV Vaccines & Microbicides Resource Tracking Working Group

8 Global HIV Prevention R&D Investment 2013 by Prevention Option (US$ millions) HIV Vaccines & Microbicides Resource Tracking Working Group

9 Global HIV Prevention R&D Investment 2012 & 2013 (US$ millions) HIV Prevention Option Amount 2013Amount 2012% Change from 2012 Preventive HIV vaccines % Microbicides % Pre-exposure Prophylaxis % Treatment as Prevention % Male circumcision % Female condoms % Prevention of vertical transmission % All HIV Prevention R&D % HIV Vaccines & Microbicides Resource Tracking Working Group

10 HIV Prevention Trial Participants by Region 2013

11 Advocacy, policy and funding trends The US public sector funds the majority of HIV prevention R&D. Philanthropic organizations increasingly fund vital parts of HIV prevention research. Industry funding stayed almost flat and shifted to later development stages. International development priorities are evolving. The enabling environment has a profound effect on where trials take place and whether they are able to happen. HIV Vaccines & Microbicides Resource Tracking Working Group

12 Acknowledgements Significant contributions from the Working Group organizations, AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS) and Working Group members Kevin Fisher (AVAC), Reuben Granich (UNAIDS), Thomas Harmon (IAVI), Polly Harrison (AVAC) and Mitchell Warren (AVAC).

13 For the full report, including graphics and past reports, visit


Download ppt "HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International."

Similar presentations


Ads by Google